Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 5Thoracic 1Other hematologic neoplasm 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 59Small Cell Lung Carcinoma 13Lung Neoplasms 13Colorectal Neoplasms 6Sarcoma 5Neoplasm Metastasis 5Melanoma 5Adenocarcinoma of Lung 4Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3NSCLC 3Carcinoma, Renal Cell 3Uterine Cervical Neoplasms 2Mesothelioma 2Extensive Stage Small Cell Lung Cancer 2Carcinoma, Hepatocellular 2Anus Neoplasms 2Uveal Melanoma 1Unresectable Stage III Non-small Cell Lung Cancer 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Testicular Germ Cell Tumor 1Small Cell Lung Cancer Extensive Stage 1SCLC, Extensive Stage 1Radiation Pneumonitis 1Perioperative Immunotherapy 1Pancreatic Neoplasms 1Non-Small Cell Lung Cancer Without Mutation in Epidermal Growth Factor Receptor (Disorder) 1Non Squamous Non-small Cell Lung Cancer 1

Interventions

pembrolizumab 8Nivolumab 6Gemcitabine 5spartalizumab 3Magnetic Resonance Spectroscopy 3Cyclophosphamide 3Azacitidine 3toripalimab 2fludarabine 2epacadostat 2atezolizumab 2Therapeutics 2Sirolimus 2Paclitaxel 2Interleukin-2 2Epoetin Alfa 2Cisplatin 2Bevacizumab 2vocimagene amiretrorepvec 1vandetanib 1ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1tislelizumab 1temsirolimus 1sargramostim 1sapanisertib 1ruxolitinib 1rucaparib 1romidepsin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × tislelizumab × Thoracic × Clear all
NCT04261439 2025-05-06

A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab

Novartis

Phase 1 Terminated
60 enrolled
DermatologicLymphoidThoracic

Carcinoma, Non-Small-Cell Lung, Lymphoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡